Rapid Micro Biosystems will release Q3 2025 financial results on November 7, with a webcast at 8:30 a.m. ET.
Quiver AI Summary
Rapid Micro Biosystems, Inc., headquartered in Lexington, Massachusetts, will announce its third quarter 2025 financial results on November 7, 2025, before the market opens. The management team will hold a webcast conference call at 8:30 a.m. ET that day, which will be available on the company's website and archived for later replay. The company specializes in life sciences technology, offering automated solutions that enhance the manufacturing process and expedite the release of healthcare products like biologics and vaccines. Their flagship product, the Growth Direct system, modernizes microbial quality control testing in pharmaceutical manufacturing, improving speed, accuracy, and compliance. Rapid Micro has facilities in the U.S. and Europe, including locations in Lowell, Switzerland, Germany, and the Netherlands.
Potential Positives
- The upcoming release of third quarter 2025 financial results demonstrates transparency and accountability, fostering investor confidence.
- The scheduled webcast conference call allows for direct communication between the company's management and stakeholders, enhancing engagement and trust.
- The Growth Direct system highlights the company's commitment to innovation and leadership in automating critical processes in healthcare manufacturing, potentially increasing market competitiveness.
Potential Negatives
- The upcoming financial results announcement may indicate that the company has not met investor expectations, as the precise timing of the release suggests a level of urgency to disclose performance metrics.
- The choice to provide detailed information about their Growth Direct system, while emphasizing its benefits, could imply that this is a crucial area where the company is currently focusing attention, potentially indicating challenges in other areas of its business.
- There may be significant scrutiny on the financial results given the ambitious claims made regarding the company's technology, which raises the stakes for positive performance outcomes.
FAQ
When will Rapid Micro Biosystems release Q3 2025 financial results?
Rapid Micro Biosystems will release its third quarter 2025 financial results on November 7, 2025.
What time is the webcast conference call?
The webcast conference call will take place at 8:30 a.m. ET on November 7, 2025.
Where can I access the live audio webcast?
The live audio webcast will be accessible on Rapid Micro Biosystems’ website through a provided link.
What is the Growth Direct system?
The Growth Direct system automates microbial quality control testing for efficient healthcare product manufacturing.
Where is Rapid Micro Biosystems headquartered?
Rapid Micro Biosystems is headquartered in Lexington, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPID Insider Trading Activity
$RPID insiders have traded $RPID stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $RPID stock by insiders over the last 6 months:
- ROBERT G. JR. SPIGNESI (PRESIDENT AND CEO) has made 0 purchases and 5 sales selling 57,443 shares for an estimated $195,955.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RPID Hedge Fund Activity
We have seen 14 institutional investors add shares of $RPID stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARKMAN HEALTHCARE PARTNERS LLC added 177,822 shares (+24.2%) to their portfolio in Q2 2025, for an estimated $613,485
- BLACKROCK, INC. removed 165,284 shares (-25.7%) from their portfolio in Q2 2025, for an estimated $570,229
- OMERS ADMINISTRATION CORP removed 109,400 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $377,430
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 106,683 shares (-67.3%) from their portfolio in Q2 2025, for an estimated $368,056
- EVERNEST FINANCIAL ADVISORS, LLC removed 87,265 shares (-66.5%) from their portfolio in Q2 2025, for an estimated $301,064
- XTX TOPCO LTD added 41,800 shares (+inf%) to their portfolio in Q2 2025, for an estimated $144,210
- CITADEL ADVISORS LLC added 20,762 shares (+inf%) to their portfolio in Q2 2025, for an estimated $71,628
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RPID Analyst Ratings
Wall Street analysts have issued reports on $RPID in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 07/28/2025
To track analyst ratings and price targets for $RPID, check out Quiver Quantitative's $RPID forecast page.
Full Release
LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2025 financial results prior to the market open on Friday, November 7, 2025.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 7, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this link . The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn .
